In January 2022, six years after the launch of Aescap Life Sciences, our second fund called Aescap Genetics was launched. The Genetics fund invests exclusively in the fast-growing market of RNA, gene and cell therapy medicines. The advantage of Genetics medicines is their ability to treat diseases at their root cause. They are not only able to treat diseases better but can also treat diseases for which no medicines are available today.
Around 125 public companies have so far launched 50 Genetics medicine and almost 900 others are being tested in humans, and these numbers are growing rapidly.
Aescap has invested in public Genetics companies since 2016 and the Aescap Genetics fund invests in approximately 15-20 companies. These companies each have the capacity to minimally double in value over 4-5 years.
The fund has a weekly liquidity with a 5-day notice period. The minimum investment amount for the Aescap Genetics fund is EUR 100.000,-. For wealth managers the minimum subscription amount is EUR 10.000,-.
ISIN Code Aescap Genetics: NL0015000PS9
Bloomberg: AESCGEI NA Equity